Glenmark has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB.

According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market achieved annual sales of approximately USD 15.2 million.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said, “The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States (US). By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.”